BiotechTube
Amador Bioscience

Amador Bioscience

Pleasanton, United States· Est.
amadorbioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Amador Bioscience is a full-service, global CRO founded in 2017, headquartered in Pleasanton, California. It offers end-to-end drug development services, leveraging its geographic footprint in the US, Europe, and China to provide local expertise and global operational capabilities. The company's integrated service model aims to bridge the gap from early translational research to regulatory approval, helping clients reduce risk, save time, and improve the success of their investigational new drug (IND) applications. Its focus spans AI/Machine Learning and Drug Delivery sectors within its service offerings.

AI / Machine LearningDrug Delivery

Technology Platform

Integrated global CRO service platform combining translational science, clinical pharmacology, bioanalysis, and clinical research operations, utilizing advanced data analysis and AI/ML techniques to optimize drug development.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

Capitalizing on the growing outsourcing trend in biopharma R&D and the specific need for high-quality, integrated CRO services.
Its strong operational footprint in both the US and China presents a unique opportunity to serve the growing demand for cross-continental drug development programs, particularly for companies seeking registration in both markets.

Risk Factors

Faces intense competition from large global CROs and niche providers.
Operational performance and regulatory compliance are critical to maintaining reputation.
Geopolitical tensions, especially between the US and China, could disrupt its integrated service model and data flow between regions.

Competitive Landscape

Competes in the fragmented global CRO market against large, full-service players (e.g., IQVIA, LabCorp, PPD), specialty pharmacology/bioanalysis labs, and regional CROs. Differentiates through its integrated 'translational-to-clinical' service model, high-touch scientific consulting, and its strategic dual-operational capability in the West and China, which is less common among mid-sized CROs.

More companies in Diagnostics & Precision Medicine →More companies in United States →